Plain-English translation of NCT06575075 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This pilot study is testing a new medication called RR-HNK (2R, 6R)-Hydroxynorketamine, which is given through an IV infusion, to see if it's safe and helpful for people with obsessive-compulsive disorder. The researchers will give some participants the medication at different doses, while others receive a placebo (saltwater), and they'll measure how people respond using brain scans and behavioral tests. The goal is to understand whether this treatment could offer hope for patients whose OCD hasn't improved with current standard treatments.
Many people with obsessive-compulsive disorder don't respond well to the treatments we have now, leaving them struggling with intrusive thoughts and repetitive behaviors that impact their daily lives. Researchers believe this medication may work differently than current OCD treatments and could help people who haven't found relief elsewhere.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll come in for an infusion appointment where you'll receive either the medication or a placebo through an IV — all participants receive just one infusion. Before and after the infusion, you'll have a brain scan (EEG) and complete some computerized behavioral tests so researchers can see how your brain and behavior respond. The study involves about 45 participants total, and it's designed to be relatively quick and straightforward, focusing mainly on understanding safety and how your body responds to the treatment.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Carolyn Rodriguez
Collaborators
National Institutes of Health (NIH)
Enrollment target
~45 participants
Started
January 2026
Primary completion
November 2028
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Izzy Vo, BS
Stanford University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.